Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: Results at 5-year followup

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 950-955

  Garzotto, Mark ^a,b   Wajsman, Zev ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hormones; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

GONADORELIN AGONIST; IODINE 125;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER;

EID: 0031932473     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63778-9     Document Type: Article

References (26)

1. Mettlin, C., Jones, G. W. and Murphy, G. P.: Trends in prostate care in the U. S., 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA, 43: 83, 1993.
2. Zietman, A. L., Coen, J. J., Shipley, W. U., Willett, C. G. and Efird, J. T.: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen as a predictor of treatment outcome. J. Urol., 151: 640, 1994.
3. Kaplan, I. D., Cox, R. S. and Bagshaw, M. A.: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J. Urol., 149: 519, 1993.
4. Hanks, G. E., Lee, R. and Schultheiss, T. E.: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J. Urol., 154: 456, 1995.
5. Zagars, G. K., von Eschenbach, A. C. and Ayala, A. G.: Prognostic factors in prostate cancer: analysis of 874 patients treated with radiation therapy. Cancer, 72: 1709, 1993.
6. Zagars, G. K. and von Eschenbach, A. C.: Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer, 72: 538, 1993.
7. Schellhammer, P. F., Kuban, D. and El-Mahdi, A. M.: Incidence and treatment: local failure after definitive treatment of carcinoma of the prostate. Urol. Clin. N. Amer., 18: 485, 1991.
8. Kuettel, M. R., Thraves, P. J., Jung, M., Varghese, S. P., Prasad, S. C., Rhim, J. S. and Dritschilo, A.: Radiation-induced neoplastic transformation of human prostate epithelial cells. Cancer Res., 56: 5, 1996.
9. Zagars, G. K., Ayala, A. G., von Eschenbach, A. C. and Pollack, A.: The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int. J. Rad. Oncol. Biol. Phys., 31: 237, 1995.
10. Pisansky, T. M., Cha, S. S., Earle, J. D., Durr, E. D., Kozelsky, T. F., Wieand, H. S. and Oesterling, J. E.: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol., 11: 2158, 1993.
11. Ahlering, T. E., Lieskovsky, G. and Skinner, D. G.: Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J. Urol., 147: 900, 1992.
12. Rogers, E., Ohori, M., Kassabian, V. S., Wheeler, T. M. and Scardino, P. T.: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J. Urol., 153: 104, 1995.
13. Lerner, S. E., Blute, M. L. and Zincke, H.: Critical evaluation of salvage surgery for radiorecurrent/resistant prostate cancer. J. Urol., 154: 1103, 1995.
14. Moul, J. W. and Paulson, D. F.: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer, 68: 1265, 1991.
15. Pontes, J. E., Montie, J., Klein, E. and Huben, R.: Salvage surgery in radiation failure for prostate cancer. Cancer, 71: 976, 1993.
16. Mador, D. R., Huben, R. P., Wajsman, Z. and Pontes, J. E.: Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate. J. Urol., 133: 58, 1985.
17. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression following radical prostatectomy. Cancer, 71: 3582, 1993.
18. Stamey, T. S., Villers, A. A., McNeal, J. E., Link, P. C. and Freiha, F. S.: Positive surgical margins at radical prostatectomy: importance of apical dissection. J. Urol., 143: 1166, 1990.
19. Soloway, M. S., Sharifi, R., Wood, D., Wajsman, Z., Mcleod, D. and Puras, A.: Randomized comparison of radical prostatectomy alone or preceded by androgen deprivation for cT2b prostate cancer. J. Urol., 154: 424, 1995.
20. Goldenberg, S. L., Klotz, L. H., Srigley, J., Jewett, M. A. S., Mador, D., Fradet, Y., Barkin, J., Chin, J., Paquin, J. M., Bullock, M. J. and Laplante, S.: Randomized, prospective controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J. Urol., 156: 873, 1996.
21. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
22. Schellhammer, P. F., Kuban, D. A. and El-Mahdi, A. M.: Treatment of clinical local failure after radiation therapy for prostate carcinoma. J. Urol., 150: 1851, 1993.
23. Pisters, L. L., von Eschenbach, A. C., Scott, S. M., Swanson, D. A., Dinney, C. P. N., Pettaway, C. A. and Babaian, R. J.: The efficacy and complications of salvage cryotherapy of the prostate. J. Urol., 157: 921, 1996.
24. Zietman, A. L., Dallow, K. C., McManus, P. A., Heney, N. M. and Shipley, W. U.: Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology, 47: 236, 1996.
25. Younes, E., Haas, G. P., Montie, J. E., Smith, J. B., Powell, I. J. and Pontes, J. E.: Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy. Urology, 43: 22, 1993.
26. DuPont, A., Cusan, L., Gomez, J., Thibeault, M., Tremblay, M. and Labrie, F.: Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J. Urol., 146: 1064, 1991.